Latest News

13 March 2018

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

CAMBRIDGE, England - Abzena plc, the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository.

The agreement with an unnamed institution will allow Abzena access to cell lines representing multiple different species, tissue types and genetic disorders. This removes the lengthy process of negotiating individual cell line licences for Abzena and its customers.

The positive impact for customers will be a more streamlined development of specialised bioassays. It will be able to provide faster, more comprehensive and more efficient functional characterisation, lead selection and potency assay development for its customers’ novel biologic drug candidates.

Dr. Campbell Bunce, SVP, Scientific Operations, commented:

“Securing access to this cell bank will be a major benefit to both us and our customers. We will be able to offer broader capabilities for evaluating and testing our customers’ drug candidates to help advance the next generation of biopharmaceuticals.”

From our portfolio

Abzena plc

Healthcare

Abzena offers product specific licences and services for the application of conjugation and polym...

viewview our portfolio

Our Team

Dr David Whitcombe

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email